Angiogenesis
Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models
Published in Medical Letter on the CDC and FDA, November 23rd, 2008
EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the publication of preclinical results for 2ME2 (Panzem(R) or 2- methoxyestradiol) in rheumatoid arthritis (RA). The results of the study, conducted by EntreMed collaborator, Dr. Ernest Brahn, Professor of Medicine, Rheumatology Program Director, David Geffen School of Medicine at UCLA, were published in the November 2008 issue of the Journal of Rheumatology (Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, and Plum SM. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses synovial...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Adverse Drug Reactions
Dermipsor Reports Positive Phase 2b Results Showing Efficacy and Synergy of its Leading Product DPS-101, a Non- Steroidal Combination Drug to Treat Psoriasis the data showed statistical significant efficacy in most arms. - Alexza Pharmaceuticals, Inc.
Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates - Cancer
Data Presented At Cancer Molecular Markers Meeting Suggests Clinical Benefit for Integrating New Molecular Tests - Fibromyalgia
Research data from M. Spaeth and colleagues update understanding of fibromyalgia - Fibromyalgia
Studies from Arizona State University add new findings in the area of fibromyalgia - Macular Degeneration
Long-Term Results of VisionCare's Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Ophthalmology - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
